Biobank for patients with large vessel occlusion stroke

Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort

This study is collecting blood and clot samples from patients with large vessel occlusion strokes to see if analyzing them can help improve diagnosis and treatment for these patients.

Quick facts

• Study type: Observational
• Enrollment: 500 (estimated)
• Sex: All
• Sponsor: First Affiliated Hospital of Wannan Medical College (Academic / other)
• Locations: 5 sites (Wuhu, Anhui and 4 other locations)
• Trial ID: NCT06963489 on ClinicalTrials.gov

What this trial studies

This multicenter, ambispective cohort study collects and analyzes blood and thrombus samples from patients with acute ischemic stroke caused by large vessel occlusion. The study aims to establish a comprehensive multiomics biobank, which includes clinical, laboratory, imaging, and follow-up data from five stroke centers. By performing detailed analyses such as metabolomics, proteomics, and genomics, researchers seek to identify phenotypic differences and develop clinical prediction models to improve diagnosis and prognosis for these patients. The rich dataset will also facilitate further scientific inquiries related to stroke.

Who should consider this trial

Good fit: Ideal candidates include adults over 18 years with confirmed large vessel occlusion ischemic stroke and available biological samples.

Not a fit: Patients who cannot provide biological samples or refuse to give informed consent will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic and prognostic tools for patients suffering from large vessel occlusion strokes.

How similar studies have performed: Other studies utilizing multiomics approaches have shown promise in understanding complex conditions, suggesting potential success for this novel approach.

Eligibility criteria

Inclusion Criteria:

1. Age over 18 years.
2. Patients with intracranial and extracranial large vessel occlusion ischemic stroke confirmed by cerebrovascular angiography.
3. Availability of complete clinical and follow-up information required for the study.
4. Availability of blood and/or thrombus biological samples.
5. Voluntary written informed consent signed by the patient or their family (1) For retrospectively enrolled patients, a "broad informed consent" was signed at the time of sample collection. Upon enrollment into the cohort, a follow-up phone call was made to confirm the informed consent.

(2) For prospectively enrolled patients, informed consent for this study was signed at the time of enrollment by the patient or their family.

Exclusion Criteria:

1. Patients for whom biological samples cannot be obtained;
2. Patients or their family members who refuse to sign the informed consent form.

Where this trial is running

Wuhu, Anhui and 4 other locations

• The First Affiliated Hospital of Shihezi University — Wuhu, Anhui, China (Not_yet_recruiting)
• Baotou Central Hospital — Baotou, Inner Mongolia, China (Recruiting)
• Affiliated Hospital of Shandong University of Traditional Chinese Medicine Hospital — Jinan, Shandong, China (Recruiting)
• The First Affiliated Hospital of zhengzhou University — Henan, Zhengzhou, China (Recruiting)
• Capital medical university of Beijing Tiantan Hospital — Beijing, China (Recruiting)

Study contacts

• Study coordinator: Zhiyuan Feng, MD

Conditions Large Vessel Occlusion; Acute Ischemic Stroke; multiomics; acute ischemic stroke with large vessel occlusion